Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 449, Issue C, Pages 64-73Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2016.11.024
Keywords
GPCR; GLP-1 secretion; Pharmacological synergy; Incretins; G protein signaling
Categories
Funding
- Novo Nordisk Foundation to University of Copenhagen
- Novo Nordisk Foundation [NNF14SA0005, NNF14OC0016798, NNF15CC0018346]
- NNF Center for Basic Metabolic Research [Schwartz Group] Funding Source: researchfish
- Novo Nordisk Fonden [NNF14OC0010889, NNF15OC0016798] Funding Source: researchfish
Ask authors/readers for more resources
GPR40 is generally known to signal through Gq. However, in transfected cells, certain synthetic agonists can make the receptor signal also through Gs and cAMP (Hauge et al., 2015). Here we find that, in colonic crypt cultures, the GLP-1 secretion induced by such Gq + Gs GPR40 agonists is indeed inhibited by blockers of both Gq and Gs and is eliminated by combining these. This in contrast to Gq-only GPR40 agonists which only are affected by the Gq inhibitor. Importantly, Gq-only GPR40 agonists in combination with low doses of selective synthetic agonists for Gs coupled receptors, e.g. GPR119 and TGR5 provide more than additive GLP-1 secretion both ex vivo and in vivo in mice. It is concluded that under physiological circumstances triglyceride metabolites, i.e. long chain fatty acids and 2-monoacyl glycerol plus bile acids, act synergistically through their respective receptors, GPR40, GPR119 and TGR5 to stimulate GLP-1 secretion robustly by combining Gq and Gs signaling pathways. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available